TIME BIOTECHNOLOGIES / KYOTO

Moving research,
toward treatment.

Patient-derived iPS cells.
A foundation for new therapeutic possibilities.

Connecting iPS technology and gene therapy.
A research-driven company based in Kyoto.

Explore our research

Conceptual visual based on a supplied image of iPS cell colonies

01 / iPS CELLS — CONCEPTUAL VISUAL FROM UNDERSTANDING
TO POSSIBILITY.

DISCOVER

In cells, we find clues to the future.

01 — 06

01 / OUR BUSINESS

ONE PLATFORM. TWO DIRECTIONS.

Two connected lines of business

One shared platform of patient-derived iPS cells.
Two ways to advance neurological disease research.

01 / CORE BUSINESS

Therapeutics for
neurological diseases

We use patient-derived iPS cells to evaluate disease biology and therapeutic candidates, connecting those findings to approaches such as base editing that aim to repair causal variants.

Explore the research pipeline

Scientific CG representing gene therapy — GENE THERAPY / CONCEPTUAL VISUAL

02 / RESEARCH SERVICES

Neurological disease research services

Contract and collaborative research spanning iPS cell establishment, quality assessment, disease modeling, and candidate efficacy or toxicity evaluation.

↗

02 / OUR BELIEF

Time is
Resource.

Time, into therapeutic possibility.

We see time as our most precious resource.
Turning the time invested in discovery into knowledge
that can lead to treatment. This is what drives our research.

Our philosophy

03 / OUR APPROACH

A CONTINUOUS PATH TO THERAPY

Understanding life.
Advancing treatment.

We use patient-derived iPS cells to model disease
and evaluate therapeutic candidates.

RESEARCH APPROACH / CONCEPTUAL VISUAL

PATIENT-DERIVED iPS CELLS

Patient-derived iPS cells

We begin with disease information carried by patient cells, using it as a foundation for understanding human disease.

DISEASE MODELING

Modeling and understanding disease

Conceptual image representing disease-model research

We derive disease-relevant cells from iPS cells and study pathological processes at the cellular level to uncover therapeutic clues.

GENE THERAPY

Translation into gene therapy

We connect discoveries from disease research to the development of gene therapies designed to act on underlying causes.

04 / RESEARCH & EVIDENCE

PUBLISHED RESEARCH

Possibility,
grounded in evidence.

Published findings, with clear attribution
and transparent research stages.

HMSN-P

Hereditary motor and sensory neuropathy
with proximal dominant involvement

Basic / preclinical research

Research aiming to correct the TFG P285L variant through base editing delivered by an AAV vector. A research group including CiRA has reported proof of concept in a mouse model and patient-derived neuromuscular organoids.

Read the published findings (CiRA)

These are published findings from an academic research group. They do not indicate a clinical trial or an approved or commercially available treatment.

RESEARCH SERVICES